Ceralasertib - Misplaced Pages

Chemical compound

Pharmaceutical compound

Ceralasertib
Clinical data

Other names	AZD-6738
Legal status
Legal status	Investigational
Identifiers
IUPAC name imino-methyl--2-(1H-pyrrolopyridin-4-yl)pyrimidin-4-yl]cyclopropyl]-oxo-lambda6-sulfane
CAS Number	1352226-88-0
PubChem CID	54761306
IUPHAR/BPS	9390
DrugBank	DB14917
ChemSpider	58828171
UNII	85RE35306Z
KEGG	D11787
ChEMBL	ChEMBL4285417
PDB ligand	VJM (PDBe, RCSB PDB)
ECHA InfoCard	100.232.607
Chemical and physical data
Formula	C₂₀H₂₄N₆O₂S
Molar mass	412.51 g·mol
3D model (JSmol)	Interactive image
SMILES C1COCCN1C2=NC(=NC(=C2)C3(CC3)(=N)(=O)C)C4=C5C=CNC5=NC=C4
InChI InChI=1S/C20H24N6O2S/c1-13-12-28-10-9-26(13)17-11-16(20(5-6-20)29(2,21)27)24-19(25-17)15-4-8-23-18-14(15)3-7-22-18/h3-4,7-8,11,13,21H,5-6,9-10,12H2,1-2H3,(H,22,23)/t13-,29-/m1/s1 Key:OHUHVTCQTUDPIJ-JYCIKRDWSA-N

Ceralasertib is an investigational new drug that is being evaluated for the treatment of cancer. It is an ATR kinase inhibitor.

References

"Ceralasertib - AstraZeneca/University of Pennsylvania". AdisInsight. Springer Nature Switzerland AG.
Mavroeidi D, Georganta A, Panagiotou E, Syrigos K, Souliotis VL (February 2024). "Targeting ATR Pathway in Solid Tumors: Evidence of Improving Therapeutic Outcomes". International Journal of Molecular Sciences. 25 (5): 2767. doi:10.3390/ijms25052767. PMC 10932434. PMID 38474014.

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.